Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.
about
Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Pembrolizumab and its role in ...... to date and clinical utility.
@en
Pembrolizumab and its role in ...... to date and clinical utility.
@nl
type
label
Pembrolizumab and its role in ...... to date and clinical utility.
@en
Pembrolizumab and its role in ...... to date and clinical utility.
@nl
prefLabel
Pembrolizumab and its role in ...... to date and clinical utility.
@en
Pembrolizumab and its role in ...... to date and clinical utility.
@nl
P2860
P356
P1476
Pembrolizumab and its role in ...... to date and clinical utility.
@en
P2093
Lapo Alinari
Polina Shindiapina
P2860
P304
P356
10.1177/2040620718761777
P577
2018-03-05T00:00:00Z